Xembify

Phase 3Small molecule

Grifols Therapeutics LLC

Xembify is one of 47 small molecule programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukemiaActive, not recruiting

CIDPRecruiting

Chronic Lymphocytic LeukemiaPhase 3

Active, not recruiting

CIDPPhase 3

Recruiting

Competition

Competitive Landscape

367 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Gazyva

Roche

Phase 3

58 2

Venclexta

AbbVie

Phase 3

50 3

Rituxan

Calquence

23 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

42 6

Nipent

Pfizer

Phase 3

13 7

Brukinsa

BBeOne Medicines

Phase 3

15 8

Medrol

Pfizer

Phase 3

1 9

Adcetris

Pfizer

Phase 3

1 10

Beqalzi

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

CIDP

NCT07540221

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Recruiting· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT05645107·386 enrolled

CIDP1 trial

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Recruiting· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT07540221·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Xembify. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xembify compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xembify. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grifols Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Grifols Therapeutics LLC

Xembify

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

CIDP1 trial

References

Drug Info

Quick Facts

Related News